News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
As part of the partnership, Boehringer Ingelheim will provide access to its opnMe® platform, enabling broader scientific exchange and driving innovation-led research.
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
C-CAMP–Imperial College London partnership to boost biotech research, startup exchange, and translational innovation through a five-year collaboration
Pharma giant targets new standards of care
Subscribe To Our Newsletter & Stay Updated
